CITIUS ONCOLOGY, INC. Quarterly Operating Income (Loss) in USD from Q1 2023 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Citius Oncology, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2023 to Q2 2024.
  • Citius Oncology, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$384K, a 92.4% decline year-over-year.
  • Citius Oncology, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$1.32M.
  • Citius Oncology, Inc. annual Operating Income (Loss) for 2023 was -$1.01M, a 633% decline from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$1.32M -$384K -$184K -92.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 -$1.13M -$268K -$121K -81.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-20
Q4 2023 -$1.01M -$244K Oct 1, 2023 Dec 31, 2023 10-K 2024-04-16
Q3 2023 -$421K Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-20
Q2 2023 -$200K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$148K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.